Drug Interactions between enfuvirtide and nirmatrelvir / ritonavir
This report displays the potential drug interactions for the following 2 drugs:
- enfuvirtide
- nirmatrelvir/ritonavir
Interactions between your drugs
ritonavir enfuvirtide
Applies to: nirmatrelvir / ritonavir and enfuvirtide
Coadministration with ritonavir and/or saquinavir may slightly increase the plasma concentrations of enfuvirtide. The mechanism of interaction is unknown. According to the manufacturer, ritonavir (200 mg every 12 hours for 4 days) increased the steady-state peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and trough concentration (Cmin) of enfuvirtide (90 mg twice a day) by 24%, 22% and 14%, respectively, in 12 HIV-positive subjects. Saquinavir-ritonavir (1000 mg-100 mg every 12 hours for 4 days) increased enfuvirtide AUC by 14% and Cmin by 26% but did not affect Cmax. These alterations are not considered to be clinically significant.
References (1)
- (2003) "Product Information. Fuzeon (enfuvirtide)." Roche Laboratories
Drug and food interactions
ritonavir food
Applies to: nirmatrelvir / ritonavir
ADJUST DOSING INTERVAL: Administration with food may modestly affect the bioavailability of ritonavir from the various available formulations. When the oral solution was given under nonfasting conditions, peak ritonavir concentrations decreased 23% and the extent of absorption decreased 7% relative to fasting conditions. Dilution of the oral solution (within one hour of dosing) with 240 mL of chocolate milk or a nutritional supplement (Advera or Ensure) did not significantly affect the extent and rate of ritonavir absorption. When a single 100 mg dose of the tablet was administered with a high-fat meal (907 kcal; 52% fat, 15% protein, 33% carbohydrates), approximately 20% decreases in mean peak concentration (Cmax) and systemic exposure (AUC) were observed relative to administration after fasting. Similar decreases in Cmax and AUC were reported when the tablet was administered with a moderate-fat meal. In contrast, the extent of absorption of ritonavir from the soft gelatin capsule formulation was 13% higher when administered with a meal (615 KCal; 14.5% fat, 9% protein, and 76% carbohydrate) relative to fasting.
MANAGEMENT: Ritonavir should be taken with meals to enhance gastrointestinal tolerability.
References (1)
- (2001) "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.